Celgene's (CELG) Deal with Juno (JUNO) 'Transformational', BMO Capital Says
Get Alerts CELG Hot Sheet
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $163 price target on Celgene (NASDAQ: CELG), calling the Juno Therapeutics (NASDAQ: JUNO) long-term collaboration on T-cell immunotherapies "transformational."
Birchenough commented, "We are reiterating our Outperform rating on the shares of CELG following its long-term collaboration for Juno. With consummation of the deal, we see CELG as exposed to a best-in-class adoptive cell therapy (ACT) platform, with resources to ā€ˇfully develop CAR-T and TCR technology optimally against what we believe to be a high hurdle in solid tumors. Ultimately, we believe that CELG immuno-oncology platform has been underestimated, with what we believe to be best-in-class structured-based antibody design and bispecific technology, now complemented by ACT technology. With multiple opportunities to succeed in large solid tumor markets, we see significant upside for CELG shares."
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $114.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enova International (ENVA) PT Raised to $62 at BMO Capital
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- CenterPoint Energy (CNP) PT Raised to $32 at BMO Capital
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!